Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hiroshi Odaguchi has a total of 57 co-authors. Here are the top co-authors by number of shared publications:

  • Sumiko Hyuga

    Laboratory of Kampo Clinical Research, Oriental Medicine Research Center, School of Pharmacy Kitasato University Tokyo Japan

    7 shared publications
  • Toshihiko Hanawa

    Oriental Medicine Therapy Center, Kitasato University Kitasato Institute Hospital, Minato-Ku, Japan

    6 shared publications
  • Masashi Hyuga

    Division of Biological Chemistry & Biologicals, National Institute of Health Sciences, 3–25–26 Tonomachi, Kawasaki-ku, Kawasaki 210–9501, Japan

    4 shared publications
  • Nahoko Uchiyama

    National Institute of Health Sciences (NIHS), 3–25–26 Tonomachi, Kawasaki-ku, Kawasaki 210–9501, Japan

    4 shared publications
  • Yukihiro Goda

    Division of Biological Chemistry & Biologicals, National Institute of Health Sciences, 3–25–26 Tonomachi, Kawasaki-ku, Kawasaki 210–9501, Japan

    4 shared publications
  • Masashi Uema

    Division of Biomedical Food Research, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki-ku, Kawasaki 210-9501, Kanagawa, Japan

    3 shared publications

Latest Publications

  • Open Access

    The Antiviral Effect of Ephedrine Alkaloids-Free Ephedra Herb Extract, EFE, on Murine Coronavirus Growth in the Lung and Liver of Infected Mice

    by Akinori Nishi, Sumiko Hyuga, Masashi Hyuga, Masashi Uema, Nahoko Uchiyama, Hiroshi Odaguchi, Yukihiro Goda

    Ephedrine alkaloids-free Ephedra Herb extract (EFE) was developed to reduce the adverse effects of Ephedra Herb, a constituent drug in Kampo medicines. It is produced by decocting Ephedra Herb with hot water and excluding the ephedrine alkaloids. EFE has analgesic and anti-cancer effects and inhibits respiratory viruses in vitro. To assess the pharmacological action of EFE in vivo, we evaluated its effect on the replication of murine hepatitis virus (MHV), a coronavirus that causes hepatitis, pneumonia, and severe acute respiratory syndrome-like symptoms, within infected mice. On Day 0, MHV was inoculated intranasally into female BALB/C mice, and EFE was orally administered once/day at 350–700 mg/kg (n = 10/group) starting 1 h after inoculation until Day 5. Through a plaque assay, MHV was detected on Day 5 in the lung and liver in all inoculated mice, but the titer was significantly lower in the EFE groups as compared with untreated control mice. Although not statistically significant, the clinical score for respiratory irregularity tended to be lower in the EFE treatment groups. In conclusion, EFE inhibits MHV replication in an in vivo mouse model of human coronavirus infection and exerts pharmacological action in the lung and liver.


  • Open Access

    Safety and Efficacy of Ephedrine Alkaloids-Free Ephedra Herb Extract (EFE) for Mild COVID-19: A Double-Blind, Placebo-Controlled, Randomized Comparative Trial

    by Hiroshi Odaguchi, Sumiko Hyuga, Mariko Sekine, Hirofumi Michimae, Masashi Hyuga, Nahoko Uchiyama, Masashi Uema, Yuji Kumagai, Yusuke Suzuki, Shigeki Nabeshima, et al.

    Several Ephedra Herb-containing Kampo medicines are common initial treatments for various infections; however, the ephedrine alkaloids in Ephedra Herb can cause side effects by stimulating adrenergic receptors. Accordingly, an ephedrine alkaloids-free Ephedra Herb Extract (EFE) has been developed. This study aimed to evaluate whether EFE can be used effectively and safely in patients with mild coronavirus disease 2019 (COVID-19). We randomized patients with mild COVID-19 to receive EFE equivalent to 6 g of Ephedra Herb per day or a placebo for 14 days. The primary efficacy endpoint was the non-aggravation rate up to Day 15. We allocated 41 and 40 patients to the EFE and placebo groups, respectively. All participants were included in the mITT and safety analysis populations [male ratio, mean age: 31.7%, 42.0 years (EFE); 17.5%, 43.2 years (placebo)]. The non-aggravation rate up to Day 15 for the primary endpoint was 100.0% and 94.6% in the EFE and placebo group, respectively, with no between-group difference. The number of days to the improvement in nausea symptoms was significantly shorter in the EFE group. One patient in the placebo group discontinued the trial due to a side effect. Although EFE demonstrated safety in patients with mild COVID-19, it did not show superior efficacy compared to placebo for symptoms other than nausea.


  • Effects of Ephedra Herb extract on the expression of EGFR-activating mutations and c-Met in non-small-cell lung cancer cell line, H1975, and its combined effects with osimertinib

    by Eiko Mori, Sumiko Hyuga, Toshihiko Hanawa, Katsuhiko Naoki, Hiroshi Odaguchi

    We previously reported that the combined application of Ephedra Herb extract (EHE) and epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), erlotinib, is effective in suppressing the growth of erlotinib-resistant non-small-cell lung cancer (NSCLC) cell line, H1993, xenograft tumor, and cell proliferation, and that EHE downregulates c-Met and wild-type EGFR in H1993 cells. However, it was unclear whether EHE could affect EGFR with active mutations. Clinically, advanced NSCLC patients who are eligible for EGFR-TKI treatment are those with detected EGFR with activating mutations. Therefore, it is important to clarify the effect of EHE on EGFR with activating mutations. H1975 cells express EGFR with activating mutations, L858R and T790M, and c-Met; this NSCLC cell line was used in the present study. EHE downregulated the expression of EGFR with activating mutations and c-Met, and inhibited autophosphorylation of c-Met. Proliferation of H1975 cells was suppressed by EHE in a concentration-dependent manner. These results suggest that EHE may be effective against NSCLC harboring EGFR with activating mutations. Considering the fact that advanced NSCLC patients, with an EGFR T790M mutation, are currently widely treated with the third-generation EGFR-TKI, osimertinib, we examined the combined effects of osimertinib and EHE on H1975 cells. The osimertinib and EHE combination downregulated the expression of these receptors and suppressed the proliferation of H1975 cells more effectively than did osimertinib alone, suggesting that this combination may be effective in treating patients with advanced NSCLC with the L858R + T790M EGFR mutation and c-Met. Graphical abstract Graphical Abstract was created with BioRender.com.


  • Open Access

    Antiviral Effect of Ephedrine Alkaloids-Free Ephedra Herb Extract against SARS-CoV-2 In Vitro

    by Masashi Uema, Masashi Hyuga, Kenzo Yonemitsu, Sumiko Hyuga, Yoshiaki Amakura, Nahoko Uchiyama, Kazushige Mizoguchi, Hiroshi Odaguchi, Yukihiro Goda

    We report for the first time that ephedrine alkaloids-free Ephedra Herb extract (EFE) directly inhibits the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro and that the addition of EFE to the culture medium before viral infection reduces virus titers in the culture supernatant of SARS-CoV-2, including those of variant strains, by more than 99%, 24 h after infection. The addition of Ephedra Herb macromolecule condensed-tannin, which is the main active ingredient responsible for the anticancer, pain suppression, and anti-influenza effects of EFE, similarly suppressed virus production in the culture supernatant by 99% before infection and by more than 90% after infection. Since EFE does not have the side effects caused by ephedrine alkaloids, such as hypertension, palpitations, and insomnia, our results showed the potential of EFE as a safe therapeutic agent against coronavirus disease 2019.


  • Open Access

    Beneficial Effect of Shishishito Administration on Anxiety and Chest Discomfort in Restlessly Speaking Patients

    by Yukiko Mori, Hiroshi Odaguchi, Toshihiko Hanawa

    梔子豉湯(山梔子と香鼓)に関する報告は少ない。今回不安感,不眠,胸部症状を落ち着きなく激しく訴えた女性6例に対し梔子豉湯を処方した。全例熱証を認めるか,あるいは冷えを認めなかった。症例1は64歳。イライラや胸の締め付けが4日で消失。症例2は63歳。心がザワザワすること,嫌な夢,みぞおちの不快感が8日後に消失。症例3は36歳。当院通院中に突然,咽のつまりと舌痛を訴えたため転方したところ5日後に消失。症例4は73歳。不安神経症の治療中に出現した不眠が転方2日で消失。症例5は84歳。不安と動悸の治療中に突然不安発作が生じたため転方したところ5日間で焦燥感が軽減。その後動悸は消失したが,不安発作が再発したため本方を再投与したところ7日間で焦燥感が軽減。症例6は48歳。身内の急死後発症したうつ病で,西洋医学的治療併用の上11日間服用したが効果はなかった。

  • Open Access

    Overlooked switch from transient sedation to sustained excitement in the Biphasic effects of Ephedra Herb extract administered orally to mice

    by Xuedan Huang, Sumiko Hyuga, Yoshiaki Amakura, Masashi Hyuga, Nahoko Uchiyama, Takashi Hakamatsuka, Yukihiro Goda, Hiroshi Odaguchi, Toshihiko Hanawa, Yoshinori Kobayashi


  • Preventive effect of a Kampo medicine, kososan, on recurrent depression in a mouse model of repeated social defeat stress

    by Naoki Ito, Kazunori Sasaki, Eiji Hirose, Takayuki Nagai, Hiroko Isoda, Hiroshi Odaguchi


  • Open Access

    Effect of Ephedra Herb on Erlotinib Resistance in c‐Met‐Overexpressing Non‐Small‐Cell Lung Cancer Cell Line, H1993, through Promotion of Endocytosis and Degradation of c‐Met

    by Sumiko Hyuga, Masashi Hyuga, Yoshiaki Amakura, Jinwei Yang, Eiko Mori, Takashi Hakamatsuka, Yukihiro Goda, Hiroshi Odaguchi, Toshihiko Hanawa

    Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR‐TKIs) are used to treat non‐small‐cell lung cancer (NSCLC), harboring an EGFR‐activating mutation. However, acquired resistance to these treatments emerges after a few years. One of causes of resistance to EGFR‐TKIs is a high level of c‐Met amplification or c‐Met protein overexpression/hyperactivation. Therefore, combination therapy with EGFR‐TKIs and a c‐Met inhibitor is thought to be effective treatment for patients with NSCLC resistance carrying c‐Met amplification and/or protein hyperactivation. Ephedra Herb is a crude drug and is used in Japan as a component in many Kampo formulae. We previously reported that Ephedra Herb extract (EHE) inhibits HGF‐induced phosphorylation of c‐Met by preventing c‐Met tyrosine kinase activity. Thus, we investigated the combination effect of EHE and erlotinib, an EGFR‐TKI, on growth of H1993 cells, an erlotinib‐resistant NSCLC cell line with overexpression of c‐Met. The EHE and erlotinib combination proved to be effective in suppression of the growth of H1993 xenograft tumors and on inhibition of proliferation of H1993 cells, suggesting that EHE is effective in rescuing NSCLC cells from erlotinib resistance. Moreover, EHE not only inhibited the phosphorylation of c‐Met, but also downregulated the expression of c‐Met by facilitating clathrin‐mediated endocytosis and lysosomal degradation of c‐Met. EHE also promoted downregulation of the expression of EGFR and phosphorylation of EGFR. Ephedrine alkaloids‐free Ephedra Herb extract (EFE) had the same effects as EHE, and the 40% MeOH fraction from EFE, which mainly contained the high‐molecular mass condensed tannins, decreased the expression levels of c‐Met, pMet, EGFR, and pEGFR to almost the same level as EFE. These results suggest that recovery from resistance to erlotinib by EHE is derived from the high‐molecular mass condensed tannins and that EHE may be suitable for treatment of c‐Met‐overexpressing NSCLC with resistance to EGFR‐TKIs.


  • Open Access

    A Double‐Blind, Randomized, Crossover Comparative Study for Evaluating the Clinical Safety of Ephedrine Alkaloids‐Free Ephedra Herb Extract (EFE)

    by Hiroshi Odaguchi, Mariko Sekine, Sumiko Hyuga, Toshihiko Hanawa, Keika Hoshi, Yoshinobu Sasaki, Masako Aso, Jinwei Yang, Masashi Hyuga, Yoshinori Kobayashi, et al.

    Ephedra Herb is an important crude drug; it is used in various Traditional Japanese Medicine (Kampo) formulations. Its significant pharmacological effects have been believed to be attributed to ephedrine and pseudoephedrine, which sometimes induce adverse effects. On the other hand, it has been reported that some of these pharmacological effects are not dependent on ephedrine or pseudoephedrine. Ephedrine alkaloids‐free Ephedra Herb extract has been newly developed. It has been reported to have analgesic, anti‐influenza, and antimetastatic effects. This clinical trial was aimed at verifying the noninferiority of EFE’s safety compared to that of Ephedra Herb extract (EHE) in humans. This was a single‐institution, double‐blinded, randomized, two‐drug, two‐stage, crossover comparative study. Twelve healthy male subjects were equally and randomly allocated into two groups: prior administration of EFE (EFE‐P) and prior administration of EHE (EHE‐P). In Stage 1, EFE and EHE were orally administered to the EFE‐P and EHE‐P groups, respectively, for six days. After a 4‐week washout period, Stage 2 was initiated wherein the subjects were given a study drug different from Stage 1 study drug for six days. Eleven adverse events with a causal relationship to the study drugs (EHE: 8; EFE: 3) were noted; all events were mild in severity. With regard to the incidence of adverse events, EHE and EFE administration, respectively, accounted for 4 cases (out of 12 subjects, similarly below) and 1 case of increased pulse rate (p=0.32) and 3 cases and 1 case of insomnia (p=0.59). Further, there was one case of hot flashes (p=1.00) due to EFE administration and one case of dysuria (p=1.00) due to EHE administration. There were no significant differences in the incidences of adverse events between EHE administration and EFE administration. Therefore, we concluded that EFE is not inferior to EHE in terms of safety.